Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 75/18.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 100/25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 125/31.25/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 150/37.5/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 175/43.75/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - levodopa, carbidopa, entacapone - film coated tablet - 200/50/200 milligram - dopa and dopa derivatives dopa and dopa derivatives

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

orion corporation - carbidopa monohydrate; levodopa - tablet - levodopa and decarboxylase inhibitor

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

orion corporation - carbidopa monohydrate; levodopa - tablet - levodopa and decarboxylase inhibitor

Spojené štáty - angličtina - NLM (National Library of Medicine)

mckesson corporation dba sky packaging - carbidopa (unii: mnx7r8c5vo) (carbidopa anhydrous - unii:kr87b45rgh), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - carbidopa anhydrous 10 mg - carbidopa and levodopa tablets usp are indicated in the treatment of parkinson's disease post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. carbidopa allows patients treated for parkinson's disease to use much lower doses of levodopa. some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets usp. this is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa. nonselective monoamine oxidase (mao) inhibitors are contraindicated for use with carbidopa and levodopa. these inhibitors must be discontinued at least two weeks prior to initiating therapy with carbidopa and levodopa. carbidopa and levodopa may be administe

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; pregelatinised maize starch; crospovidone; quinoline yellow aluminium lake; microcrystalline cellulose - levodopa/carbidopa gppl is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gppl frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.